The oral environment has received various amounts of attention in association with HIV infection and pathogenesis. Since HIV infection occurs through mucosal tissue, oral factors—including tissue, fluids, and compartments—are of interest in furthering our understanding of the diagnosis, infectivity, transmission, and pathogenesis of disease. This report reviews: (1) HIV testing and diagnoses with oral fluids; (2) post-natal acquisition of HIV in association with breast-feeding from HIV-positive mothers; and (3) oral sex and HIV transmission. In the first, we examine how oral fluids are used to detect HIV infection and review current consensus on the role of salivary molecules as markers for immunosuppression. Second, lactation-associated HIV acquisition is reviewed, with special consideration of emerging issues associated with the impact of anti-retroviral therapies. Last, we consider current data on the risk of HIV infection in association with oral sex. Investigation of these diverse topics has a common goal: understanding how HIV presents in the oral environment, with an aim to rapid and accessible HIV diagnosis, and improved prevention and treatment of infection.
Get full access to this article
View all access options for this article.
References
1.
Baba TW, Trichel AM, An L, Liska V, Martin LN, Murphey-Corb M, et al. (1996). Infection and AIDS in adult macaques after nontraumatic oral exposure to cell-free SIV. Science272:1486–1489.
2.
Balls J, Evans J, Dilley J, et al. (2004). No incident HIV infections among MSM who practice exclusively oral sex. International Conference on AIDS, Bangkok, Thailand 2004; Oral poster presentation WePpC2072.
3.
Baqui A, Meiller T, Jabra-Rizk M, Zhang M, Kelley J, Falkler W (1999a). Association of HIV viral load with oral diseases. Oral Dis5:294–298.
4.
Baqui AA, Meiller TF, Falkler WA Jr (1999b). Enhanced secretory leukocyte protease inhibitor in human immunodeficiency virus type 1-infected patients. Clin Diagn Lab Immunol6:808–811.
5.
Barr CE, Miller LK, Lopez MR, Croxson TS, Schwartz SA, Denman H, et al. (1992). Recovery of infectious HIV-1 from whole saliva. J Am Dent Assoc123:36–37, 39–48.
6.
Barret B, Tardieu M, Rustin P, Lacroix C, Chabrol B, Desguerre I, et al. (2003). Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS17:1769–1785.
7.
Bertolli J, St Louis ME, Simonds RJ, Nieburg P, Kamenga M, Brown C, et al. (1996). Estimating the timing of mother-to-child transmission of human immunodeficiency virus in a breast-feeding population in Kinshasa, Zaire. J Infect Dis174:722–726.
8.
Bobat R, Moodley D, Coutsoudis A, Coovadia H (1997). Breastfeeding by HIV-1-infected women and outcome in their infants: a cohort study from Durban, South Africa. AIDS11:1627–1633.
9.
Bulterys M, Chao A, Dushimimana A, Saah A (1995). HIV-1 seroconversion after 20 months of age in a cohort of breastfed children born to HIV-1-infected women in Rwanda. AIDS9:93–94.
10.
Centers for Disease Control and Prevention (CDC) (1997). Transmission of HIV possibly associated with exposure of mucous membrane to contaminated blood. Morbid Mortal Wkly Rep46:620–623.
11.
Celum CL, Buchbinder SP, Donnell D, Douglas JM Jr, Mayer K, Koblin B, et al. (2001). Early human immunodeficiency virus (HIV) infection in the HIV Network for Prevention Trials Vaccine Preparedness Cohort: risk behaviors, symptoms, and early plasma and genital tract virus load. J Infect Dis183:23–35.
12.
Chen W, Samarasinghe PL (1992). Allergy, oral sex, and HIV [letter]. Lancet339:627–628.
13.
Chohan BH, Lavreys L, Mandaliya KN, Kreiss JK, Bwayo JJ, Ndinya-Achola JO, et al. (2001). Validation of a modified commercial enzyme-linked immunoassay for detection of human immunodeficiency virus type 1 immunoglobulin G antibodies in saliva. Clin Diagn Lab Immunol8:346–348.
14.
Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, et al. (2002). Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr29:484–494.
15.
Coutsoudis A, Dabis F, Fawzi W, Gaillard P, Haverkamp G, Harris DR, et al. (2004). Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis. J Infect Dis189:2154–2166.
16.
Cunningham CK, Chaix ML, Rekacewicz C, Britto P, Rouzioux C, Gelber RD, et al. (2002). Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. J Infect Dis186:181–188.
17.
Dabis F, Msellati P, Meda N, Welffens-Ekra C, You B, Manigart O, et al. (1999). 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d’Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. DITRAME Study Group. DIminution de la TRAnsmission Mêre-Enfant. Lancet353:786–792.
18.
Darrow WW, Echenberg DF, Jaffe HW, O’Malley PM, Byers RH, Getchell JP, et al. (1987). Risk factors for human immunodeficiency virus (HIV) infections in homosexual men. Am J Public Health77:479–483.
19.
Datta P, Embree JE, Kreiss JK, Ndinya-Achola JO, Braddick M, Temmerman M, et al. (1994). Mother-to-child transmission of human immunodeficiency virus type 1: report from the Nairobi Study. J Infect Dis170:1134–1140.
20.
DeGruttola V, Mayer KH (1987). Human immunodeficiency virus and oral intercourse. Ann Intern Med107:428–429.
21.
Del Romero J, Marincovich B, Castilla J, Garcia S, Campo J, Hernando V, et al. (2002). Evaluating the risk of HIV transmission through unprotected orogenital sex. AIDS16:1296–1297.
22.
Detels R, English P, Visscher BR, Jacobson L, Kingsley LA, Chmiel JS, et al. (1989). Seroconversion, sexual activity, and condom use among 2915 HIV seronegative men followed for up to 2 years. J Acquir Immune Defic Syndr2:77–83.
23.
Dorenbaum A, Cunningham CK, Gelber RD, Culnane M, Mofenson L, Britto P, et al. (2002). Two–dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. J Am Med Assoc288:189–198.
24.
Ekpini ER, Wiktor SZ, Satten GA, Adjorlolo-Johnson GT, Sibailly TS, Ou CY, et al. (1997). Late postnatal mother-to-child transmission of HIV-1 in Abidjan, Côte d’Ivoire. Lancet349:1054–1059.
25.
Embree JE, Njenga S, Datta P, Nagelkerke NJ, Ndinya-Achola JO, Mohammed Z, et al. (2000). Risk factors for postnatal mother-child transmission of HIV-1. AIDS14:2535–2541.
26.
Eshleman SH, Guay LA, Mwatha A, Brown ER, Cunningham SP, Musoke P, et al. (2004). Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6–8 weeks after single-dose nevirapine (HIVNET 012). J Acquir Immune Defic Syndr35:126–130.
27.
Fawzi W, Msamanga G, Spiegelman D, Renjifo B, Bang H, Kapiga S, et al. (2002). Transmission of HIV-1 through breastfeeding among women in Dar es Salaam, Tanzania. J Acquir Immune Defic Syndr31:331–338.
28.
Frerichs RR, Htoon MT, Eskes N, Lwin S (1992). Comparison of saliva and serum for HIV surveillance in developing countries. Lancet340:1496–1499.
29.
Gaillard P, Fowler MG, Dabis F, Coovadia H, Van Der Horst C, Van Rompay K, et al. (2004). Use of antiretroviral drugs to prevent HIV-1 transmission through breast-feeding: from animal studies to randomized clinical trials. J Acquir Immune Defic Syndr35:178–187.
30.
Gallo D, George JR, Fitchen JH, Goldstein AS, Hindahl MS (1997).Evaluation of a system using oral mucosal transudate for HIV-1 antibody screening and confirmatory testing. OraSure HIV Clinical Trials Group. J Am Med Assoc277:254–258.
31.
Goldberg DJ, Green ST, Kennedy DH, Emslie JA, Black JD (1988). HIV and orogenital transmission [letter]. Lancet2:1363.
32.
Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, et al. (1999). Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet354:795–802.
33.
Jackson JB, Becker-Pergola G, Guay LA, Musoke P, Mracna M, Fowler MG, et al. (2000). Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS14:F111–F115.
34.
Jackson JB, Musoke P, Fleming T, Guay LA, Bagenda D, Allen M, et al. (2003). Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet362:859–868.
35.
John-Stewart G, Mbori-Ngacha D, Ekpini R, Janoff EN, Nkengasong J, Read JS, et al. (2004). Breast-feeding and transmission of HIV-1. J Acquir Immune Defic Syndr35:196–202.
36.
Kantor R, Zijenah LS, Shafer RW, Mutetwa S, Johnston E, Lloyd R, et al. (2002). HIV-1 subtype C reverse transcriptase and protease genotypes in Zimbabwean patients failing antiretroviral therapy. AIDS Res Hum Retroviruses18:1407–1413.
37.
Keet IP, Albrecht van Lent N, Sandfort TG, Coutinho RA, van Griensven GJ (1992). Orogenital sex and the transmission of HIV among homosexual men. AIDS6:223–226.
38.
Kingsley LA, Detels R, Kaslow R, Polk BF, Rinaldo CR Jr, Chmiel J, et al. (1987). Risk factors for seroconversion to human immunodeficiency virus among male homosexuals. Results from the Multicenter AIDS Cohort Study. Lancet1:345–349.
39.
Lane HC, Holmberg SD, Jaffe HW (1991). HIV seroconversion and oral intercourse [letter]. Am J Public Health81:658.
40.
Lee EJ, Kantor R, Zijenah L, Sheldon W, Emel L, Mateta P, et al. (2005).Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapine. J Infect Dis192:1260–1264.
41.
Leigh JE, Steele C, Wormley FL Jr, Luo W, Clark RA, Gallaher W, et al. (1998). Th1/Th2 cytokine expression in saliva of HIV-positive and HIV-negative individuals: a pilot study in HIV-positive individuals with oropharyngeal candidiasis. J Acquir Immune Defic Syndr Hum Retrovirol19:373–380.
42.
Leroy V, Karon JM, Alioum A, Ekpini ER, van de Perre P, Greenberg AE, et al. (2003). Postnatal transmission of HIV-1 after a maternal short-course zidovudine peripartum regimen in West Africa. AIDS17:1493–1501.
43.
Lifson AR (1988). Do alternate modes for transmission of human immunodeficiency virus exist? A review. J Am Med Assoc259:1353–1356.
44.
Lyman D, Winkelstein W, Ascher M, Levy JA (1986). Minimal risk of transmission of AIDS-associated retrovirus infection by oral-genital contact [letter]. J Am Med Assoc255:1703.
45.
Maher D, Wu X, Schacker T, Larson M, Southern P (2004). A model system of oral HIV exposure, using human palatine tonsil, reveals extensive binding of HIV infectivity, with limited progression to primary infection. J Infect Dis190:1989–1997.
46.
Malamud D (1997). Oral diagnostic testing for detecting human immunodeficiency virus-1 antibodies: a technology whose time has come. Am J Med102:9–14.
47.
Marseille E, Kahn JG, Mmiro F, Guay L, Musoke P, Fowler MG, et al. (1999). Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa. Lancet354:803–809.
48.
Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al. (1997). Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med126:946–954.
49.
Miotti PG, Taha TE, Kumwenda NI, Broadhead R, Mtimavalye LA., Van der Hoeven L, et al. (1999). HIV transmission through breastfeeding: a study in Malawi. J Am Med Assoc282:744–749.
50.
Mirochnick M, Fenton T, Gagnier P, Pav J, Gwynne M, Siminski S, et al. (1998). Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis178:368–374.
51.
Moodley D, Moodley J, Coovadia H, Gray G, McIntyre J, Hofmyer J, et al. (2003). A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis187:725–735.
52.
Murray AB, Greenhouse PR, Nelson WL, Norman JE, Jeffries DJ, Anderson J (1991). Coincident acquisition of Neisseria gonorrhoeae and HIV from fellatio [letter]. Lancet338:830.
53.
Musoke P, Guay LA, Bagenda D, Mirochnick M, Nakabiito C, Fleming T, et al. (1999). A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS13:479–486.
54.
Nishanian P, Aziz N, Chung J, Detels R, Fahey JL (1998). Oral fluids as an alternative to serum for measurement of markers of immune activation. Clin Diagn Lab Immunol5:507–512.
55.
Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts (2000). J Acquir Immune Defic Syndr25:261–268.
56.
Page-Shafer K, Veugelers PJ, Moss AR, Strathdee S, Kaldor JM, van Griensven GJ (1997). Sexual risk behavior and risk factors for HIV-1 seroconversion in homosexual men participating in the Tricontinental Seroconverter Study, 1982–1994. Am J Epidemiol146:531–542.
57.
Page-Shafer K, Shiboski CH, Osmond DH, Dilley J, McFarland W, Shiboski SL, et al. (2002). Risk of HIV infection attributable to oral sex among men who have sex with men and in the population of men who have sex with men. AIDS16:2350–2352.
58.
Richardson BA, John-Stewart GC, Hughes JP, Nduati R, Mbori-Ngacha D, Overbaugh J, et al. (2003). Breast-milk infectivity in human immunodeficiency virus type 1-infected mothers. J Infect Dis187:736–740.
59.
Rothenberg RB, Scarlett M, del Rio C, Reznik D, O’Daniels C (1998). Oral transmission of HIV. AIDS12:2095–2105.
60.
Rozenbaum W, Gharakhanian S, Cardon B, Duval E, Coulaud JP (1988). HIV transmission by oral sex [letter]. Lancet1:1395.
61.
Safrit JT, Ruprecht R, Ferrantelli F, Xu W, Kitabwalla M, Van Rompay K, et al. (2004). Immunoprophylaxis to prevent mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr35:169–177.
62.
Samuel MC, Hessol N, Shiboski S, Engel RR, Speed TP, Winkelstein W Jr (1993). Factors associated with human immunodeficiency virus seroconversion in homosexual men in three San Francisco cohort studies, 1984–1989. J Acquir Immune Defic Syndr6:303–312.
63.
Schechter MT, Boyko WJ, Douglas B, Maynard M, Willoughby B, McLeod A, et al. (1986a). Can HTLV-III be transmitted orally? [letter]. Lancet1:379.
64.
Schechter MT, Boyko WJ, Douglas B, Willoughby B, McLeod A, Maynard M, et al. (1986b). The Vancouver Lymphadenopathy-AIDS Study: 6. HIV seroconversion in a cohort of homosexual men. Can Med Assoc J135:1355–1360.
65.
Semba RD, Neville MC (1999). Breast-feeding, mastitis, and HIV transmission: nutritional implications. Nutr Rev57:146–153.
66.
Semba RD, Kumwenda N, Taha TE, Hoover DR, Quinn TC, Lan Y, et al. (1999). Mastitis and immunological factors in breast milk of human immunodeficiency virus-infected women. J Hum Lact15:301–306.
67.
Shaffer N, Bulterys M, Simonds RJ (1999). Short courses of zidovudine and perinatal transmission of HIV. N Engl J Med340:1042–1043.
68.
Shetty AK, Coovadia HM, Mirochnick MM, Maldonado Y, Mofenson LM, Eshleman SH, et al. (2003). Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months. J Acquir Immune Defic Syndr34:482–490.
Spitzer PG, Weiner NJ (1989). Transmission of HIV infection from a woman to a man by oral sex [letter]. N Engl J Med320:251.
71.
Sweet SP, Rahman D, Challacombe SJ (1995). IgA subclasses in HIV disease: dichotomy between raised levels in serum and decreased secretion rates in saliva. Immunology86:556–559.
72.
Sweet SP, Denbury AN, Challacombe SJ (2001). Salivary calprotectin levels are raised in patients with oral candidiasis or Sjögren’s syndrome but decreased by HIV infection. Oral Microbiol Immunol16:119–123.
Van Rompay KK, McChesney MB, Aguirre NL, Schmidt KA, Bischofberger N, Marthas ML (2001). Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection. J Infect Dis184:429–438.
76.
Van Rompay KK, Greenier JL, Cole KS, Earl P, Moss B, Steckbeck JD, et al.(2003). Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251. J Virol77:179–190.
77.
Vittinghoff E, Douglas J, Judson F, McKirnan D, MacQueen K, Buchbinder SP (1999). Per-contact risk of human immunodeficiency virus transmission between male sexual partners. Am J Epidemiol150:306–311.
78.
Wiktor SZ, Ekpini E, Karon JM, Nkengasong J, Maurice C, Severin ST, et al. (1999). Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d’Ivoire: a randomised trial. Lancet353:781–785.
79.
Winkelstein W Jr, Lyman DM, Padian N, Grant R, Samuel M, Wiley JA, et al. (1987). Sexual practices and risk of infection by the human immunodeficiency virus. The San Francisco Men’s Health Study. J Am Med Assoc257:321–325.
